Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imdusiran - Arbutus Biopharma

Drug Profile

Imdusiran - Arbutus Biopharma

Alternative Names: AB-729; ARB 270729

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arbutus Biopharma
  • Developer Antios Therapeutics; Arbutus Biopharma; Assembly Biosciences
  • Class Amides; Amino sugars; Antivirals; Drug conjugates; Small interfering RNA
  • Mechanism of Action Hepatitis B surface antigen expression inhibitors; Hepatitis B virus replication inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis B

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D

Most Recent Events

  • 08 Jan 2024 Arbutus Biopharma plans a phase IIa AB-729-203 trial for Hepatitis (Combination therapy) in H1 of 2024
  • 08 Jan 2024 Arbutus Biopharma plans a phase IIa trial in combination with an approved PD-L1 monoclonal antibody in H1 of 2024
  • 04 Dec 2023 Arbutus Biopharma plans a phase II i-LIVER trial for Hepatitis B in December 2023 (SC) (NCT06154278)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top